Antengene
RESEARCH FIELD

R&D and Innovation

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

Candidate Molecule

Target/
Mechanism

Rights

Preclinical

IND

Phase I

Phase II

Phase Ⅲ

NDA

Partner

  • PD-L1
  • Worldwide
  • MSI-H/dMMR advanced cancer (mono, 2L+)

  • Advanced BTC (combo with chemo vs. chemo, 1L)

  • NSCLC (vs standard treatment)

  • NSCLC (combo with chidamide, 2L+)

  • UC (mono vs. BSC, 1L maintenance, MRCT)

  • G/GEJ advanced cancer (combo with chemo, 1L)

  • TMB-H advanced cancer (mono, 2L+)

  • EC (mono and combo with lenvatinib, 2L+)

  • NSCLC, HCC, RCC (combo with lenvatinib)

  • HCC, CRC, NSCLC (combo with BD0801)

  • Alphamab Group

    Simcere Group
    (CSO)

    TRACON
    (Sarcoma, Phase II)
  • WT1
  • Greater China
  • Multiple indications

  • SELLAS Group
  • GAS6/AXL
  • Greater China
  • Healthy Volunteers

  • NSCLC/RCC/UC

  • PROC

    (MRCT)

  • Aravive
  • COX-2
  • China
  • Post-surgical dental pain/cancer pain

  • Haihe Biopharma Group
  • EP-4
  • China
  • Cancer pain / osteoarthritis

  • Haihe Biopharma Group
  • FGFR1/2/3
  • Worldwide
  • Locally advanced or metastatic solid tumors

  • Haihe Biopharma Group & SIMM
  • TKI prodrug
  • Worldwide
  • Advanced malignant solid tumors

  • CD47
  • Greater China
  • Multiple indications

  • ImmuneOncia
  • CD3+PD-L1
  • Greater China + Worldwide Priority Transfer right
  • Multiple indications

  • Y-Biologics
  • WT1
  • Greater China
  • Multiple indications

  • SELLAS Group
  • Sema4D
  • Worldwide
  • Multiple indications

  • KRAS
  • Worldwide
  • Multiple indications

  1. Envafolimab
  2. 3D189
  3. 3D229
  4. 3D1001
  5. 3D1002
  6. 3D185
  7. 3D011
  8. 3D197
  9. 3D057
  10. 3D059
  11. 3D060
  12. 3D062